Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03464994
Other study ID # RC31/17/0067
Secondary ID 2017-A00605-48
Status Recruiting
Phase N/A
First received November 18, 2017
Last updated March 7, 2018
Start date July 18, 2017
Est. completion date July 18, 2018

Study information

Verified date March 2018
Source University Hospital, Toulouse
Contact Juliette MAZEREEUW, MD
Phone 05 67 77 81 41
Email mazereeuw-hautier.j@chu-toulouse.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Presence/absence of subclinical keratoconus with corneal topographic abnormalities (skewed radial axes for forme fruste keratoconus, and inferior steepening for keratoconus suspect) on axial specular topography (TMS-4 Tomey), and elevation topographies: Pentacam (Oculus) and Orbscan (Bausch & Lomb).


Description:

Background: Hereditary ichthyosis are rare genetic diseases characterized by an abnormal epithelial keratinization due to mutations in gene involved in skin barrier. Patients present with scales on the whole body. Recent classification basically distinguishes syndromic from non-syndromic forms. Ichthyoses are severe diseases with significant impact on quality of life, due to troublesome symptoms (pruritus, pain), lack of effective therapy and complications such as ophthalmological anomalies. Among ophthalmological abnormalities, some are well known, such as eyelid abnormalities, including ectropion, and sicca syndrome. Conversely, corneal abnormalities such as keratoconus are not or very partially described in ichthyosis. The keratoconus is characterized by a corneal thickening and bulging with progressive loss of vision that may require a corneal transplantation. Its prevalence is 0.05% in its symptomatic presentation but may reach 10% when considering subclinical keratoconus diagnosed on basis of corneal topographies. These forme fruste keratoconus or keratoconus suspect may remain subclinical or instead progress to severe keratoconus. Corneal collagen crosslinking has been shown to strengthen the cornea in order to halt progressive keratoconus, justifying the need for early screening. Keratoconus is a complex condition of multifactorial etiology. With regards to the pathophysiology of the keratoconus, some hypotheses incriminate the corneal epithelial differentiation that is similar to the epidermal differentiation altered in ichthyosis. This link between both dermatological and ophthalmological abnormalities is supported by clinical experience. It's was observed that ichthyosis patients have frequently a subclinical keratoconus. In clinical practice, ophthalmological abnormalities are not commonly investigated in ichthyosis patients and there are no data on prevalence in the literature. Furthermore, there are no guidelines on screening or therapy of ophthalmological abnormities in ichthyosis.

The purpose of this project is to demonstrate that the prevalence of subclinical keratoconus (including forme fruste keratoconus and keratoconus suspect) is higher in ichthyosis compared to healthy controls.

Descriptive analysis of the studied population for primary outcome: The proportion of patients with subclinical keratoconus (including form fruste keratoconus and keratoconus suspect) will be described in each study-group and compared between study-groups using Mac Nemar Test.


Recruitment information / eligibility

Status Recruiting
Enrollment 152
Est. completion date July 18, 2018
Est. primary completion date July 18, 2018
Accepts healthy volunteers No
Gender All
Age group 6 Years and older
Eligibility Inclusion Criteria:

For ichthyosis population:

- Hereditary ichthyosis, whatever form or ongoing therapy.

- Parental permission for minors

For controls:

- Patients who consult an ophthalmologist for refractive surgery screening or systematic eye examination

- Parental permission for minors

Exclusion Criteria:

For both populations:

- Patient who cannot stay seated

- Wearing contact lens within the last 7 days

- No social security

- Past medical history of corneal or eye surgery or eye condition (glaucoma, uveitis, keratoconus, retinal diseases)

- Impossibility to fill the questionnaires

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
ophthalmological examination
Refraction Best corrected visual acuity Intraocular pressure Slit lamp examination with vital dye (Oxford grading) Tear break-up time (TBUT) Schirmer I testing Specular (TMS-4 Tomey) and elevation (pentacam Oculus and Orbscan Bausch & Lomb) corneal videotopographies Pachymetry Questionnaires: Ocular surface disease index, quality of vision (visual analogic scale), and quality of life (NEI-VFQ25) questionnaire about ichthyosis severity questionnaire about life quality specifically for patient presenting ichthyosis

Locations

Country Name City State
France University Hospital of Toulouse Toulouse

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Toulouse Association for the development of research in Dermatology

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Presence/absence of subclinical keratoconus Presence/absence of subclinical keratoconus with corneal topographic abnormalities (skewed radial axes for forme fruste keratoconus, and inferior steepening for keratoconus suspect) on axial specular topography (TMS-4 Tomey), and elevation topographies: Pentacam (Oculus) and Orbscan (Bausch & Lomb). 10 mn
Secondary Presence/absence of symptomatic keratoconus with irregular topographic maps Evaluation by corneal videotopographies 10 mn
Secondary Presence/absence of an abnormality of corneal transparency Evaluated by the measurement of the refraction, 10 mn
Secondary Presence/absence of sicca syndrome Examination with the slit lamp of eyelids and eyelashes 10 mn
Secondary Evaluation of quality of vision -Ocular Surface Disease Index (OSDI) : Self administered form to evaluate the impact of dry eye on visual function : 12 questions rated from 0 (never) to 4 (all the time) 10 mn
Secondary Quality of life for adults -Quality of life by the National Eye Institute Visual Function Questionnaire (NEI-VFQ) : Self-administered questionnaire witch incorporates a wider range of data in relation to quality of life related to vision. Each question leads to an answer that is either dichotomous (yes / no), or graduated in 3, 4.5 and 6 points. The score of each item is transformed from 0 to 100, and the average of the scores by domain is established. 10 mn
See also
  Status Clinical Trial Phase
Completed NCT03051347 - Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments N/A
Completed NCT00004690 - Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis Phase 3
Completed NCT00074685 - National Registry for Ichthyosis and Related Disorders
Completed NCT03641261 - Therapeutic Education Using an Internet Application in Hereditary Ichthyosis N/A
Completed NCT03796052 - Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients N/A
Recruiting NCT05954416 - FARD (RaDiCo Cohort) (RaDiCo-FARD)
Active, not recruiting NCT05295732 - The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis Phase 3
Terminated NCT02655861 - A Multi-center, Prospective Evaluation of Infants and Children With Congenital Ichthyosis
Recruiting NCT03417856 - Defining the Skin and Blood Biomarkers of Ichthyosis
Terminated NCT04697056 - A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis Phase 2
Recruiting NCT06330350 - Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
Enrolling by invitation NCT06330324 - Reproductive Options in Inherited Skin Diseases
Completed NCT03041038 - The Efficacy and Safety of Secukinumab in Patients With Ichthyoses Phase 2
Not yet recruiting NCT06362447 - Efficacy of Injectable Gentamicin in Hereditary Ichthyosis Phase 2
Active, not recruiting NCT04549792 - An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses Early Phase 1